News

The collaboration is aimed at O-GIcNAcase, a target for Alzheimer’s, that modulates the solubility of the protein in these aggregates but that has been difficult to target with

In conjunction with the sublicensing agreement, Topica Pharmaceuticals will now focus on developing Luliconazole exclusively for the treatment of onychomycosis. Reportedly, in February of 2010 the company’s IND

The combined entity, called Valeant Pharmaceuticals International, will have a significantly expanded presence in North America and operations across eight other countries. The deal is expected to take

The decision comes a year after Marubeni transferred sales and marketing of F310 Polyvinylidene Chloride (PVDC) product to Viachem from Univar’s ChemPoint business unit. Marubeni claimed that its

The new oxymorphone formulation is a semi-synthetic opioid analgesic intended for the treatment of moderate to severe chronic pain in patients requiring continuous, around-the-clock opioid treatment for an

Tamaris is a randomised, double blind, placebo controlled study designed to evaluate the safety and efficacy of NV1FGF in patients with critical limb ischemia and skin lesions who

Most recently, McElroy has worked with Chiltern International for over two years as the executive director of Strategic Development, Americas. Before joining Chiltern, he served as the vice

OctoPlus said that the undisclosed contract value will make a material contribution to its’ annual revenues. As per the contract terms, OctoPlus is expected to perform clinical manufacturing

The Promus Element Stent features a new Platinum chromium (PtCr) alloy and new stent design, which combine to offer greater radial strength and flexibility while reducing stent recoil.